Navigation Links
Mylan Launches Generic Version of Cyklokapron® Injection
Date:12/2/2011

PITTSBURGH, Dec. 2, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its business Mylan Institutional has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Tranexamic Acid Injection, 100 mg/mL, packaged in 1,000 mg/10 mL Single-dose Vials. This product is the generic version of Pharmacia & Upjohn's Cyklokapron® Injection, which is indicated for short-term use in patients with hemophilia to reduce or prevent hemorrhage during and following oral surgery.

Tranexamic Acid Injection had U.S. sales of approximately $17 million for the 12 months ending Sept. 30, 2011, according to IMS Health. Mylan is shipping this product immediately.

Currently, Mylan has 165 ANDAs pending FDA approval representing $99.4 billion in annual sales, according to IMS Health. Forty-three of these pending ANDAs are potential first-to-file opportunities, representing $26.9 billion in annual brand sales, for the 12 months ending June 30, 2011, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Mylan Receives Tentative FDA Approval Through PEPFAR for First Heat-Stable, Fixed-Dose Combination of Atazanavir Sulfate and Ritonavir Tablets for HIV/AIDS
2. Mylan Launches Generic Version of Caduet® Tablets
3. Mylan Confirms First-to-File Patent Challenge Relating to Generess™ Fe
4. Mylan Committed to Expanding Access in Developing Countries to High Quality, Affordable HIV/AIDS Treatment
5. Mylan Receives Approval for Generic Version of Zinecard® for Injection
6. Mylan Announces Settlement Agreement for its First-to-File Generic Version of Vivelle-Dot®
7. Mylan Successfully Upsizes and Completes Refinancing of Credit Facility
8. Mylan Applauds Obama Administrations Call to Create an "AIDS-Free Generation" Through Global Fight Against HIV/AIDS
9. Mylan to Acquire Pfizer Respiratory Delivery Platform
10. Mylan Receives Approval for Generic Version of MS Contin® Tablets
11. Mylan Launches First Generic Version of Exelon® Capsules in the U.K.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... Oregon and PUNE, India ... to a new report published by Allied Market Research, ... Global Opportunity Analysis and Industry Forecast, 2014-2022," the global ... by 2022, from $5,768 million in 2015, growing at ... chemical & gas sterilization segment dominated the market in ...
(Date:1/16/2017)... 16, 2017 Transparency Market Research states ... Devices Market  held a huge share of 43% in 2015. ... frontrunners in the overall market, grabbing the undivided attention of ... across geographies, and strong product portfolio is expected to keep ... ...
(Date:1/16/2017)... 16, 2017  Dovetail Genomics today announced the commercial ... service, which yields chromosome-scale genome assemblies. The service is ... workshop on Jan. 17 at the Plant & Animal ... . "We are thrilled to be ... our Dovetail Hi-C offering," said Todd Dickinson , ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... January 16, 2017 , ... ... demonstrate their groundbreaking GunSport•PRO® and EB15•LE® electronic earplugs at the NSSF SHOT Show ... Vegas, Booth #2809. The SHOT Show is the shooting, hunting and outdoor trade ...
(Date:1/16/2017)... Smithtown, New York (PRWEB) , ... January 16, ... ... group, SightMD today announced the addition of Victor Giamos, MD to ... Officer of SightMD and Managing Partner at North Shore Eye Care, a division ...
(Date:1/16/2017)... St. Louis, MO (PRWEB) , ... January 16, 2017 , ... St. Louisans are well-aware ... is here , This year’s influenza shot seems to be having no effect ... public area, at least half of the people around are coughing, sneezing, or sniffling ...
(Date:1/16/2017)... ... 2017 , ... One thing common to all types of cancer is that ... well. The money spent screening for and treating cancer in the United States is ... cancer more than in any other country that has an advanced healthcare system, sometimes ...
(Date:1/15/2017)... ... January 15, 2017 , ... In this role, Courtney will be responsible ... the asthma & allergy friendly mark. This certification program was created by ASL and ... products to be more suitable for the 60+ million people living in the U.S. ...
Breaking Medicine News(10 mins):